CORT News Alert Corcept Therapeutics Inc (CORT) 3.15 02/13/2015

New Post Public Reply Private Reply Replies (0) Message Board

Feb 14, 2015 at 12:13 AM

Corcept Therapeutics Inc (CORT) 3.15 $CORT

Cortendo's resolutions on new share issues at Extraordinary General Meeting approved
M2 - Wed Feb 04, 5:28AM CST
Cortendo AB (NOTC-A:CORT)(OTC:CRTOF), a biopharmaceutical company focused on orphan endocrine disorders, on Tuesday reported the holding of an Extraordinary General Meeting in Goteborg.
CORT: 3.15 (+0.01)

Earnings Update: Corcept Therapeutics
Clinically Sound Investor - at Seeking Alpha - Fri Jan 30, 1:13PM CST

CORT: 3.15 (+0.01)

Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Jan 29, 10:34PM CST

CORT: 3.15 (+0.01)

Corcept Therapeutics beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 3:24PM CST

CORT: 3.15 (+0.01)

Corcept Therapeutics Announces Fourth Quarter and Full Year 2014 Revenue, Provides 2015 Revenue Guidance and Clinical Update
Marketwired - Thu Jan 29, 3:08PM CST
Corcept Therapeutics Incorporated (NASDAQ: CORT)
CORT: 3.15 (+0.01)

Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Jan 28, 4:35PM CST

VR: 42.10 (+0.07), BXP: 141.08 (-1.58), EPAY: 27.07 (+0.64), CPSI: 53.11 (+0.26), GOOG: 549.01 (+6.08), PKI: 46.30 (-0.10), JDSU: 13.26 (+0.23), TFSL: 14.47 (+0.18), MITK: 3.38 (-0.02), NFG: 65.15 (+0.60), EFII: 40.59 (+0.94), BCR: 175.38 (+0.50), MCHP: 50.71 (+0.73), PMCS: 9.24 (+0.07), PFPT: 55.97 (+0.38), ABAX: 60.93 (+0.65), CPHD: 59.62 (+0.72), PFG: 51.60 (+0.50), QLGC: 14.48 (+0.48), UIS: 23.37 (+0.27), TUES: 19.41 (-0.01), COHR: 64.95 (+0.25), PCCC: 23.66 (+0.05), CTCT: 42.48 (+0.72), BIIB: 391.66 (-0.45), SFG: 67.49 (+0.21), IXYS: 11.92 (-0.07), SYNA: 78.91 (+0.87), HLIT: 7.90 (+0.01), INVN: 16.08 (+0.09), CB: 102.06 (+0.43), N: 101.72 (+3.38), ELX: 6.57 (+0.22), GIMO: 21.45 (+1.10), SWI: 50.55 (+0.79), V: 269.63 (-1.28), ELY: 8.61 (-0.05), GDOT: 15.54 (+0.34), FICO: 82.00 (+1.50), HBI: 119.12 (+1.27), ISBC: 11.70 (+0.07), NATI: 31.20 (+0.31), NEU: 469.55 (+0.43), AMZN: 381.83 (+4.66), EMN: 75.67 (+0.56), ALGN: 56.90 (-0.34), BRCM: 45.69 (+0.23), HA: 18.72 (-0.31), DECK: 77.08 (+0.61), LEG: 44.90 (+0.17), MTW: 21.86 (+0.34), RVBD: 20.85 (-0.03), AVNW: 1.19 (+0.08), RHI: 61.42 (+0.04), NGVC: 30.28 (+0.45), CORT: 3.15 (+0.01)

Corcept reports January 29
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 3:34PM CST

CORT: 3.15 (+0.01)

Corcept Therapeutics to Announce Fourth Quarter and Full Year 2014 Revenue and Corporate Update and Host Conference Call
Marketwired - Thu Jan 22, 3:05PM CST
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full year 2014 revenue on January 29, 2015. The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
CORT: 3.15 (+0.01)

Commit To Buy Corcept Therapeutics At $3, Earn 26.7% Annualized Using Options
StockOptionsChannel.com - Mon Jan 05, 10:38AM CST
Investors considering a purchase of Corcept Therapeutics Inc shares, but cautious about paying the going market price of $3.12/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting...
CORT: 3.15 (+0.01)

Zacks Rank #5 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
COWN: 4.76 (+0.06), BWS: 29.28 (+0.12), CORT: 3.15 (+0.01), CLRO: 10.39 (+0.24), CALD: 14.95 (+0.03)

Will Corcept (CORT) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 10:23AM CST
Will Corcept (CORT) Continue to Surge Higher?
CORT: 3.15 (+0.01)

Moving Average Crossover Alert: Corcept Therapeutics (CORT) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 8:27AM CST
Moving Average Crossover Alert: Corcept Therapeutics (CORT)
CORT: 3.15 (+0.01)

Global Cushing's Syndrome Therapeutics Market 2015-2019: Key Vendors are Corcept Therapeutics, HRA Pharma and Novartis
M2 - Thu Nov 20, 5:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/wvdxbs/global_cushings) has announced the addition of the "Global Cushing's Syndrome Therapeutics Market 2015-2019" report to their offering. One major trend upcoming in this market is the increase in public awareness of Cushing's syndrome. This is expected to lead to an increase in the number of treatment-seeking patients, thereby giving rise to the consumption of medications. According to the report, the major driving factor of the market is the presence of a huge unmet need in this rare disease area. Few FDA-approved drugs are available, and the use of off-label drugs can cause several adverse effects. Thus, drug makers have the opportunity to produce therapies which can give them an edge over others and seize a major portion of the total market. Further, the report states that the adverse effects of the drugs used to treat Cushing's syndrome are a major challenge to the growth of the market. Patient incompatibility leads to an increase in the churn-out rate of the patients from the treatment. This results in restraining the market growth. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Product Profiles 05. Market Research Methodology 06. Introduction 07. Disease Overview 08. Market Landscape 09. Market Segmentation by Class of Drugs 10. Market Segmentation by Route of Administration 11. Market Segmentation by Dosage Form 12. Geographical Segmentation 13. Buying Criteria 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Pipeline Portfolio 22. Key Vendor Analysis 23. Other Reports in this Series Companies Mentioned: - Corcept Therapeutics - HRA Pharma - Novartis - Aspireo Pharmaceuticals - Cortendo - ElexoPharm - Ipsen - Isis Pharmaceuticals - Orphagen Pharmaceuticals - Samaritan Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/wv...l_cushings
ISIS: 63.86 (-0.43), CORT: 3.15 (+0.01), NVS: 102.20 (-0.17)

Corcept posts 3Q loss
Automated Insights - Tue Nov 04, 5:15PM CST
MENLO PARK, Calif. (AP) _ Corcept Therapeutics Inc. (CORT) on Tuesday reported a loss of $6 million in its third quarter.
CORT: 3.15 (+0.01)

Corcept Therapeutics beats by $0.03, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 3:28PM CST

CORT: 3.15 (+0.01)

Corcept Therapeutics Announces Third Quarter 2014 Financial Results and Provides Corporate Update
Marketwired - Tue Nov 04, 3:09PM CST
Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders, today reported its financial results for the quarter ended September 30, 2014. The company also provided an update on its clinical programs and revised its 2014 revenue guidance.
CORT: 3.15 (+0.01)

Notable earnings after Tuesday's close
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 4:35PM CST

AMRS: 2.09 (+0.30), ITRI: 35.75 (-0.12), AWAY: 29.68 (+0.11), OKE: 47.32 (+0.04), HR: 28.69 (-0.08), NYMT: 7.75 (+0.05), OCLR: 1.55 (+0.09), ENPH: 15.15 (+0.37), ADEP: 6.93 (-0.30), CBSO: 27.51 (+0.58), NSTG: 12.66 (-0.11), MITT: 18.52 (+0.08), CRTO: 40.70 (+0.41), FOXA: 34.72 (+0.31), OKS: 45.47 (+0.07), JMBA: 14.50 (-0.61), IVR: 15.33 (+0.01), CSU: 24.59 (+0.03), MYGN: 34.03 (+0.40), JIVE: 5.34 (+0.02), GAS: 50.07 (+0.27), COUP: 11.06 (-0.07), NRP: 7.86 (-0.45), MOSY: 2.10 (+0.02), COHR: 64.95 (+0.25), DOX: 51.15 (+0.37), CKEC: 29.96 (+0.89), OAS: 16.84 (-0.03), PAYC: 32.37 (-0.71), PCYC: 163.28 (+0.23), AXLL: 47.40 (+0.51), NP: 62.15 (-0.52), BIRT: 6.60 (+0.01), ATVI: 23.11 (+0.17), EXAM: 39.97 (+0.31), P: 15.44 (+0.45), JAZZ: 169.69 (+6.89), PBPB: 13.92 (-0.07), EXEL: 2.48 (+0.20), CERS: 5.53 (+0.08), DVN: 66.47 (+0.69), FEYE: 42.26 (+2.63), CHUY: 22.04 (-0.35), FRGI: 61.80 (-0.33), GHDX: 31.12 (+0.28), PACD: 3.76 (+0.16), BIO: 118.36 (+0.79), BIOL: 2.22 (+0.22), JKHY: 65.78 (+0.52), KAR: 35.64 (-0.03), CDXS: 3.42 (+0.07), MPO: 1.00 (-0.02), FANG: 73.46 (+0.49), CORT: 3.15 (+0.01), CALD: 14.95 (+0.03)

Corcept reports November 4
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 3:56PM CDT

CORT: 3.15 (+0.01)

Corcept Therapeutics to Announce Third Quarter Financial Results and Host Conference Call
Marketwired - Tue Oct 28, 3:08PM CDT
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 4, 2014. The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
CORT: 3.15 (+0.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LINC Lawsuit: Boardroom Stumbles Spark Investor Action

Class Action Kickoff: Lincoln's Educational Curveball No one fancies home runs when the ball’s out of sight, and that’s probably how some investors in Lincoln Educational Services Corporation (NASDAQ: LINC) are feeling right now. A group of shareholders has pulled back the curtain on what they believe are more than just administrative hiccups—allegations of...

Ruth E. Carter Returns Home with Celebrated Exhibition

Ruth E. Carter’s Triumphant Return When a titan of the costume design world circles back to their roots, you know it’s bound to be something special. Ruth E. Carter, who has swapped needles and threads for Oscars (twice, mind you), is making a return to Hampton University, paying homage to the very soil that sowed her artistic seeds. Ain't that a capstone of a career...

Venue Two Eleven: Historic Charm Meets Modern Events

Welcome To Venue Two Eleven: Where History Meets Modernity Alright, folks. Let’s talk about Venue Two Eleven—a new joint in town that’s blending the old with the new in a way that’s got me raising an eyebrow and maybe even sipping my coffee a little slower. Nestled in the Museum of the Oregon Territory, this place is pulling double duty as both a window to the...

Kansai Medical Ushers in New Era of Cancer Research

Breaking Ground in Cancer Treatment Trials I've seen some thrilling breakthroughs in my time following the pharmaceutical industry, but what Kansai Medical University and Daiichi Sankyo are doing elevates the game. They're rolling out the first patient dose of DS1025 in Osaka, Japan—a move that marks the onset of a global Phase 1 clinical trial. This is no ordinary...

Alaska LNG Project Boosted by Strategic Positioning

Alaska LNG: Right Place, Right Time Someone bring out the confetti, because Paul Sullivan, Co-Chairman of Gastech, is celebrating Alaska LNG like it's 1999. And for good reason. If Alaska ever played its cards right, now's the moment according to the industry veteran. After Gastech 2026 wrapped its events in Bangkok last month, Sullivan laid out why the stars are aligning...

U.S. Millionaire Surge: Market Waves or Mirage?

Flashing Billions: Minting Millionaires at Breakneck Speed It sounds like something out of an 80s movie: every single day, over 1,200 folks in the United States become millionaires. Yep, you heard right. The UBS Global Wealth Report 2026 threw that number out, and it sure caught my attention. It's not everyday you hear about the U.S. cranking out millionaires like they're...

Costa Rican Firms Chase Growth at SIAL Paris 2026

Chasing Growth in Paris: Costa Rica's Bold Move When it comes to playing the global field, Costa Rica isn't just sitting back; they're on the move. Picture this: PROCOMER, along with 18 standout companies, landed smack dab in the grand hustle and bustle of SIAL Paris 2026. This isn't some leisurely stroll—it's a calculated sprint toward expanding their reach across...

Spooky Suds: House of Horror Meets El Car Wash

A Haunted Wash Awaits Miami Drivers Picture this: you're cruising down West Flagler on a regular Wednesday evening, but tonight, you're not just rolling in for a rinse. Nope, this Wednesday night, the wash tunnel at El Car Wash gets downright spooky. It's getting a haunted house makeover with scare actors from the House of Horror. When a Car Wash Becomes a Haunted...

Spire's Year-End Call: Eyes on Earnings & Guidance

Anticipation Builds for Spire's Upcoming Earnings Call If you're keen on natural gas and the energy sector, keep a firm grip on your coffee cup because Spire Inc. (NYSE: SR) is about to spill the beans on their fiscal 2026 financials. Mark your calendars for November 17. Whether you're tuning in via phone or hitching a ride on the webcast, you're in for an earful. Time...

Richard Huffman Joins IFA Board, Strengthens Franchise Ties

Ever wonder how the cogs in this massive machine called franchising keep turning? It's folks like Richard Huffman who step up to the plate, and his recent election to the International Franchise Association (IFA) Board of Directors is worth a second glance. Huffman: A Franchise Veteran Now, Huffman isn't some rookie in the world of franchising. You see, back in '94, he...